| Abstrakt: |
A study conducted in Shanghai, China explored the correlation between serum anti-tumor necrosis factor (TNF) levels and early endoscopic response in patients with active Crohn's disease (CD). The study found that higher levels of infliximab (IFX) and adalimumab (ADA), two anti-TNF monoclonal antibodies, were associated with endoscopic response in CD patients. The researchers developed a nomogram prediction model based on laboratory markers and therapeutic drug monitoring (TDM) to evaluate the primary endoscopic response to anti-TNF therapy. This study provides valuable insights for optimizing treatment strategies and switching therapy in CD patients. [Extracted from the article] |
